NLS Pharmaceutics AG has announced a significant update to its merger and reorganization plans with Kadimastem Ltd. The two companies have entered into a Fifth Amendment to their Agreement of Merger and Plan of Reorganization. This amendment, effective as of July 1, 2025, involves NLS Pharmaceutics Ltd., its Israeli subsidiary NLS Pharmaceuticals (Israel) Ltd., and Kadimastem Ltd., an Israeli publicly traded company. The amendment outlines further commitments to carry out the merger provisions and signifies continued progress towards the planned reorganization. The companies involved have expressed their commitment to executing the necessary documents and actions to fulfill the amendment's provisions.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。